Search
for
Sort by
Research 301–330 of 661
- Efectos adversos dermatológicos con uso de litio
- Bakteriyel Selüloz Tabanlı Hidrojel Taşıyıcı ile Topikal Uygulanan Tideglusib’in Sıçanlarda Oluşturulan Palatinal Yaranın İyileşmesi Üzerine Etkisinin Makroskobik Değerlendirmesi: Bir Öncül Çalışma
- Myo-inositol in polycystic ovary syndrome: a systematic review and positioning of its use
- Industry update: the latest developments in the field of therapeutic delivery, July 2018
- 289 Immortalization of primary human dermal papilla cells by Bmi-1 and TERT
- Rosemary bioactive phytochemicals as a strategy for the management of age related conditions
- Sexual dimorphism of COVID-19 inspires drug repositioning and host-targeting immunotherapy for viral pneumonia
- How Long to Treat to Achieve Desired Treatment Outcomes with Baricitinib 4 mg in Severe Alopecia Areata: Evidence-based Approach
- The effects and mechanisms of collagen peptides for alleviating skin ageing
- Circulating MicroRNA Signatures in Severe Alopecia Areata: Diagnostic Discrimination, Pathway Analysis, and Therapeutic Implications
- Lgr5 Stem Cells and Potential Treatments for Hair Loss
- Responses to Tetanus and Meningococcal Vaccines in Patients with Alopecia Areata Treated with Ritlecitinib
- Scalp cooling and chemotherapy-induced alopecia: Evaluating cost-effectiveness and insurance coverage
- Gender based price differences in 5% minoxidil foam: The impact of generic alternatives and bulk packaging
- Safety and Efficacy of Mesotherapy with Placenta Polypeptide Injection for Moderate-to-Severe Sensitive Skin: A Multicenter, Randomized, Controlled Trial
- Optimasi Kombinasi Ramuan Etnomedisin Penumbuh Rambut Nusa Tenggara Timur Menggunakan Orthogonal Stimulus Response Method Pada Kepadatan Rambut Mencit (Mus musculus)
- Most Baricitinib Responders Achieved Full Scalp Hair Regrowth: Findings from Adult and Paediatric BRAVE-AA Trials
- Efficacy, Safety, and Tolerability of Upadacitinib in Adults and Adolescents With Severe Alopecia Areata: Results From the Randomized, Placebo-Controlled, Double-Blind Phase 3 Program (UP-AA)
- Baricitinib Provides Significant Hair Regrowth In Adolescents With Severe Alopecia Areata: 52-Week Efficacy and Safety Results From A Phase 3 Randomized, Controlled Trial
- Baricitinib Provides Holistic Improvement in Scalp, Eyebrow and Eyelash Regrowth in Adolescents With Severe Alopecia Areata
- Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata
- Comparative analysis of stemness between dermal papilla cells and human dermalstem/progenitor cells
- Prediction of Long-term Scalp Hair Regrowth at 24 Months in Patients with Alopecia Areata Receiving Ritlecitinib Treatment in the ALLEGRO Clinical Trial Program
- Nouvelles thérapeutiques dans la prise en charge de l’alopécie androgénétique
- Understanding the Experience of Healthcare Access and Health-Related Impacts among Individuals with Alopecia Areata
- A concise review- Development of an analytical method and validation of dutasteride
- EARLY CARDIAC DAMAGE FOLLOWING SINGLE AND COMBINED EXPOSURE TO LITHIUM CARBONATE AND LEAD ACETATE IN RATS: A TOXICOLOGICAL PERSPECTIVE
- THE MULTIFACETED APPROACH TO POLYCYSTIC OVARIAN SYNDROME: A REVIEW OF TRADITIONAL AND ALLOPATHIC MEDICINE
- Hair follicle stem cells promote epidermal regeneration under expanded condition
- The study of the range and availability of Vitamin D 3 preparations in the pharmaceutical market of Ukraine